Immunodeficiency disorders or diseases render the ability of the immune system to fight against microbial infection, thus making a person immuno-compromised. Thus, people suffering from immunodeficiency diseases or disorders are more likely to fall sick. An immunodeficiency disorder may be either congenital or acquired. Congenital immunodeficiency disorder refers to the one which occurs by birth while acquired disorder refers to the one which occurs later in life. For instance, primary immunodeficiency disease is a congenital immunodeficiency disease which is a result of defect in genes that regulate the immune system. These genes are involved in functioning of immune organs such as spleen, lymph nodes, bone marrow, tonsils, and others. Some of the common primary immunodeficiency diseases include X-linked agammaglobulinemia (XLA), common variable, immunodeficiency (CVID), and severe combined immunodeficiency (SCID). Human immunodeficiency virus, spleen removal surgery, unsanitary conditions, and malnutrition are the most common causes of immunodeficiency disorders. Immunodeficiency diseases or disorders may exhibit signs such as yeast infection, cold, pink eye, diarrhea, pneumonia, and others. Recent advances in the field of immunology and genetics has created large number of opportunities for development and commercialization of newer, safer, and more efficient immunodeficiency therapeutics.
Market Dynamics
Market players are conducting clinical trials for developing safer and more efficient treatments for immunodeficiency diseases, which could contribute to the growth of the global immunodeficiency therapeutics market over the forecast period. For instance, in March 2017, Octapharma AG, a Switzerland based pharmaceutical company initiated phase III clinical trial study to investigate the efficiency, safety and tolerability of its product Octanorm (cutaquig) which is a ready to use liquid formulation of normal human IgG to be administered subcutaneously for treatment of primary immunodeficiency disease. The results for this clinical study were published by PubMed in April 2020, and show that Octanorm, manufactured by Octapharma AG is safe for indicated use.
Market players are focusing on launch of products, which is expected to strengthen their position in the global immunodeficiency therapeutics market. For instance, in June 2019, Octapharma AG launched its new product called cutaquig which is a 16.5% immune globulin solution to be used for treatment of primary humoral immunodeficiency.
Market players are involved in inorganic business strategies such a partnership to strengthen their position globally, this is expected to drive the growth of the global immunodeficiency therapeutics market. For instance, in January 2020, SAB Biotherapeutics Inc., a U.S. based biotechnology company entered into a collaborative partnership with CSL Behring, a U.S. based biopharmaceutical company to carry out research based on novel therapies which could be used for treatment of immune disorders such as chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), primary immunodeficiency disease, and others.
Key features of the study:
- This report provides an in-depth analysis of global immunodeficiency therapeutics market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
- It profiles leading players in the global immunodeficiency therapeutics market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
- Key companies covered as a part of this study include Pfizer Inc., CSL Behring, Grifols, S.A., Abbott, ADMA Biologics, Inc., AstraZeneca, Baxter, Bayer AG, Biocon, Bristol-Myers Squibb Company, BDI Pharma, Inc., Bharat Serums and Vaccines Ltd., Eli Lilly and Company, GlaxoSmithKline plc., Lupin Pharmaceuticals Inc., Novartis AG, Octapharma AG, Sanofi, and Takeda Pharmaceutical Company Limited
- Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
- The global immunodeficiency therapeutics market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global immunodeficiency therapeutics market
Detailed Segmentation:
- Global Immunodeficiency Therapeutics Market, By Therapy Type:
- Immunoglobulin Therapy
- Antibiotics Therapy
- Stem Cell and Gene Therapy
- Others
- Global Immunodeficiency Therapeutics Market, By Test Type:
- Blood Test
- Prenatal Testing
- Global Immunodeficiency Therapeutics Market, By Disease Type:
- Antibody Deficiency
- Cellular Immunodeficiency
- Innate Immune Disorders
- Others
- Global Immunodeficiency Therapeutics Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Global Immunodeficiency Therapeutics Market, By Region:
- North America
- By Therapy Type:
- Immunoglobulin Therapy
- Antibiotics Therapy
- Stem Cell and Gene Therapy
- Others
- By Test Type:
- Blood Test
- Prenatal Testing
- By Disease Type:
- Antibody Deficiency
- Cellular Immunodeficiency
- Innate Immune Disorders
- Others
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country:
- Latin America
- By Therapy Type:
- Immunoglobulin Therapy
- Antibiotics Therapy
- Stem Cell and Gene Therapy
- Others
- By Test Type:
- Blood Test
- Prenatal Testing
- By Disease Type:
- Antibody Deficiency
- Cellular Immunodeficiency
- Innate Immune Disorders
- Others
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Therapy Type:
- Immunoglobulin Therapy
- Antibiotics Therapy
- Stem Cell and Gene Therapy
- Others
- By Test Type:
- Blood Test
- Prenatal Testing
- By Disease Type:
- Antibody Deficiency
- Cellular Immunodeficiency
- Innate Immune Disorders
- Others
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- Asia Pacific
- By Therapy Type:
- Immunoglobulin Therapy
- Antibiotics Therapy
- Stem Cell and Gene Therapy
- Others
- By Test Type:
- Blood Test
- Prenatal Testing
- By Disease Type:
- Antibody Deficiency
- Cellular Immunodeficiency
- Innate Immune Disorders
- Others
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Therapy Type:
- Immunoglobulin Therapy
- Antibiotics Therapy
- Stem Cell and Gene Therapy
- Others
- By Test Type:
- Blood Test
- Prenatal Testing
- By Disease Type:
- Antibody Deficiency
- Cellular Immunodeficiency
- Innate Immune Disorders
- Others
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Therapy Type:
- Immunoglobulin Therapy
- Antibiotics Therapy
- Stem Cell and Gene Therapy
- Others
- By Test Type:
- Blood Test
- Prenatal Testing
- By Disease Type:
- Antibody Deficiency
- Cellular Immunodeficiency
- Innate Immune Disorders
- Others
- By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Pfizer Inc.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- CSL Behring
- Grifols, S.A.
- Abbott
- ADMA Biologics, Inc.
- AstraZeneca
- Baxter
- Bayer AG
- Biocon
- Bristol-Myers Squibb Company
- BDI Pharma, Inc.
- Bharat Serums and Vaccines Ltd.
- Eli Lilly and Company
- GlaxoSmithKline plc.
- Lupin Pharmaceuticals Inc.
- Novartis AG
- Octapharma AG
- Sanofi
- Takeda Pharmaceutical Company Limited
“*” marked represents similar segmentation in other categories in the respective section.
